BresaGen executes supply contracts
Friday, 27 January, 2006
Adelaide biotechnology manufacturer BresaGen (ASX:BGN) has executed supply contracts worth AUD$680,000 with WA based junior biotech Caldeon and Brisbane's Tissue Therapies (ASX:TIS).
Caldeon is collaborating with the University of Western Australia to optimise osteoporosis drug leads which could reduce bone loss.
BresaGen offers process development and manufacture of recombinant peptides and proteins providing an alternative to peptide manufacture using chemical synthesis. The company has a proprietary fusion protein system that allows high level expression and inclusion body formation of proteins and peptides in E. Coli.
BresaGen has now provided several Australian biotech companies with process development and supply of material for various stages of product development including, CBio, Hunter Immunology, QRx, Imugene (ASX:IMU) and Psiron (ASX:PSX).
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
